Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 243 citing articles:

Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population
Jonathan J. Lau, Samuel M. S. Cheng, Kathy Leung, et al.
Nature Medicine (2023) Vol. 29, Iss. 2, pp. 348-357
Open Access | Times Cited: 145
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Annaliesa S. Anderson, Patrick Caubel, James M. Rusnak
New England Journal of Medicine (2022) Vol. 387, Iss. 11, pp. 1047-1049
Open Access | Times Cited: 95
Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID‐19: A rapid review and meta‐analysis
Behnam Amani, Bahman Amani
Journal of Medical Virology (2022) Vol. 95, Iss. 2
Open Access | Times Cited: 87
Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
Joseph A. Lewnard, John M. McLaughlin, Deborah E. Malden, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 7, pp. 806-815
Open Access | Times Cited: 86
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shmuel Shoham, Carolina Batista, Yanis Ben Amor, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101965-101965
Open Access | Times Cited: 84
Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK
Ivan Chun Hang Lam, Carlos King Ho Wong, Ran Zhang, et al.
EClinicalMedicine (2023) Vol. 60, pp. 102000-102000
Open Access | Times Cited: 72
Effectiveness of COVID-19 Treatment With Nirmatrelvir–Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 6, pp. 807-816
Open Access | Times Cited: 70
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China
Liyan Yang, Zhonglei Wang
European Journal of Medicinal Chemistry (2023) Vol. 257, pp. 115503-115503
Open Access | Times Cited: 63
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
Bin Cao, Yeming Wang, Hongzhou Lu, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 3, pp. 230-241
Open Access | Times Cited: 59
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Jennifer Hammond, Robert J. Fountaine, Carla Yunis, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1186-1195
Open Access | Times Cited: 59
Nirmatrelvir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records
Yan Xie, Benjamin Bowe, Ziyad Al‐Aly
BMJ (2023), pp. e073312-e073312
Open Access | Times Cited: 53
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 6, pp. 683-695
Open Access | Times Cited: 45
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
Yuming Sun, Liping Jin, Yating Dian, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101981-101981
Open Access | Times Cited: 45
Nirmatrelvir–ritonavir for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Huzaifa Ahmad Cheema, Uzair Jafar, Aruba Sohail, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 2
Closed Access | Times Cited: 41
Recent Advances in Covalent Drug Discovery
D. M. Schaefer, Xinlai Cheng
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 663-663
Open Access | Times Cited: 39
COVID-19 drug discovery and treatment options
Jasper Fuk‐Woo Chan, Shuofeng Yuan, Hin Chu, et al.
Nature Reviews Microbiology (2024) Vol. 22, Iss. 7, pp. 391-407
Closed Access | Times Cited: 17
The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Chih‐Cheng Lai, Ya‐Hui Wang, Kuang-Hung Chen, et al.
Viruses (2022) Vol. 14, Iss. 8, pp. 1706-1706
Open Access | Times Cited: 59
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes
Kristina L. Bajema, Kristin Berry, Elani Streja, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 46
Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
Luca Cegolon, Riccardo Pol, Omar Simonetti, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 721-721
Open Access | Times Cited: 35
Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Hospitalized Patients With COVID-19
Eric Yuk Fai Wan, Vincent Ka Chun Yan, Anna Hoi Ying Mok, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 4, pp. 505-514
Open Access | Times Cited: 33
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Daniele Focosi, Scott A. McConnell, Shmuel Shoham, et al.
International Journal of Antimicrobial Agents (2023) Vol. 61, Iss. 2, pp. 106708-106708
Open Access | Times Cited: 31
Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: A systematic review and meta‐analysis
Fangyuan Tian, Zhaoyan Chen, Qiyi Feng
Journal of Medical Virology (2023) Vol. 95, Iss. 4
Closed Access | Times Cited: 31
An explanation for SARS-CoV-2 rebound after Paxlovid treatment
Alan S. Perelson, Ruy M. Ribeiro, Tin Phan
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top